{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:09:13Z","timestamp":1788390553709,"version":"build-2803163510"},"reference-count":53,"publisher":"Innovative Healthcare Institute","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treatment option for highly aggressive B cell malignancies. Clinical trials of CD19 CAR T cells for the management of relapsed and\/or refractory non-Hodgkin lymphoma (NHL) have shown markedly improved survival and response rates. The goal of this review is to evaluate whether the results from these clinical trials are reflective of real-world practices through the analysis of published literature of the commercially available CAR T cell products. We have found that despite the significantly different patient characteristics, the adverse events and response rates of real-world patients were similar to those of the clinical trials. Of interest, several groups excluded from the clinical trials, such as patients with HIV infection, chronic viral hepatitis, and secondary CNS (central nervous system) lymphoma, had case reports of promising outcomes.<\/jats:p>","DOI":"10.36401\/jipo-21-2","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T13:07:56Z","timestamp":1628168876000},"page":"150-159","source":"Crossref","is-referenced-by-count":24,"title":["Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?"],"prefix":"10.36401","volume":"4","author":[{"given":"Kevin","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"2021080516155697600_i2590-017X-4-3-150-b01","doi-asserted-by":"crossref","unstructured":"Abramson\n              JS,\n            \n            \n              Palomba\n              ML,\n            \n            \n              Gordon\n              LI,\n            \n            et al.\n          \n          Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2020;\n\t\t\t\t\t396:\n\t\t\t\t\t839\u2013\n\t\t\t\t\t852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"2021080516155697600_i2590-017X-4-3-150-b02","doi-asserted-by":"crossref","unstructured":"Neelapu\n              SS,\n            \n            \n              Locke\n              FL,\n            \n            \n              Bartlett\n              NL,\n            \n            et al.\n          \n          Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t377:\n\t\t\t\t\t2531\u2013\n\t\t\t\t\t2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"2021080516155697600_i2590-017X-4-3-150-b03","doi-asserted-by":"crossref","unstructured":"Schuster\n              SJ,\n            \n            \n              Bishop\n              MR,\n            \n            \n              Tam\n              CS,\n            \n            et al.\n          \n          Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t380:\n\t\t\t\t\t45\u2013\n\t\t\t\t\t56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"2021080516155697600_i2590-017X-4-3-150-b04","doi-asserted-by":"crossref","unstructured":"Wang\n              M,\n            \n            \n              Munoz\n              J,\n            \n            \n              Goy\n              A,\n            \n            et al.\n          \n          KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2020;\n\t\t\t\t\t382:\n\t\t\t\t\t1331\u2013\n\t\t\t\t\t1342.","DOI":"10.1056\/NEJMoa1914347"},{"key":"2021080516155697600_i2590-017X-4-3-150-b05","doi-asserted-by":"crossref","unstructured":"Levine\n              BL,\n            \n            \n              Miskin\n              J,\n            \n            \n              Wonnacott\n              K,\n            \n            et al.\n          \n          Global manufacturing of CAR T cell therapy.\n\t\t\t\t\tMol Ther Methods Clin Dev.\n\t\t\t\t\t2017;\n\t\t\t\t\t4:\n\t\t\t\t\t92\u2013\n\t\t\t\t\t101.","DOI":"10.1016\/j.omtm.2016.12.006"},{"key":"2021080516155697600_i2590-017X-4-3-150-b06","doi-asserted-by":"crossref","unstructured":"Tyagarajan\n              S,\n            \n            \n              Spencer\n              T,\n            \n            \n              Smith\n              J.\n            \n          \n          Optimizing CAR-T cell manufacturing processes during pivotal clinical trials.\n\t\t\t\t\tMol Ther Methods Clin Dev.\n\t\t\t\t\t2020;\n\t\t\t\t\t16:\n\t\t\t\t\t136\u2013\n\t\t\t\t\t144.","DOI":"10.1016\/j.omtm.2019.11.018"},{"key":"2021080516155697600_i2590-017X-4-3-150-b07","doi-asserted-by":"crossref","unstructured":"Jain\n              MD,\n            \n            \n              Jacobs\n              M,\n            \n            \n              Nastoupil\n              LJ,\n            \n            et al.\n          \n          Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2019;\n\t\t\t\t\t134(suppl 1):\n\t\t\t\t\t245.","DOI":"10.1182\/blood-2019-129624"},{"key":"2021080516155697600_i2590-017X-4-3-150-b08","doi-asserted-by":"crossref","unstructured":"Pinnix\n              CC,\n            \n            \n              Gunther\n              JR,\n            \n            \n              Dabaja\n              BS,\n            \n            et al.\n          \n          Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma.\n\t\t\t\t\tBlood Adv.\n\t\t\t\t\t2020;\n\t\t\t\t\t4:\n\t\t\t\t\t2871\u2013\n\t\t\t\t\t2883.","DOI":"10.1182\/bloodadvances.2020001837"},{"key":"2021080516155697600_i2590-017X-4-3-150-b09","doi-asserted-by":"crossref","unstructured":"Wrzesinski\n              C,\n            \n            \n              Paulos\n              CM,\n            \n            \n              Kaiser\n              A,\n            \n            et al.\n          \n          Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.\n\t\t\t\t\tJ Immunother.\n\t\t\t\t\t2010;\n\t\t\t\t\t33:\n\t\t\t\t\t1\u2013\n\t\t\t\t\t7.","DOI":"10.1097\/CJI.0b013e3181b88ffc"},{"key":"2021080516155697600_i2590-017X-4-3-150-b10","doi-asserted-by":"crossref","unstructured":"Hirayama\n              AV,\n            \n            \n              Gauthier\n              J,\n            \n            \n              Hay\n              KA,\n            \n            et al.\n          \n          The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2019;\n\t\t\t\t\t133:\n\t\t\t\t\t1876\u2013\n\t\t\t\t\t1887.","DOI":"10.1182\/blood-2018-11-887067"},{"key":"2021080516155697600_i2590-017X-4-3-150-b11","doi-asserted-by":"crossref","unstructured":"Innamarato\n              P,\n            \n            \n              Kodumudi\n              K,\n            \n            \n              Asby\n              S,\n            \n            et al.\n          \n          Reactive myelopoiesis triggered by lymphodepleting chemotherapy limits the efficacy of adoptive T cell therapy.\n\t\t\t\t\tMol Ther.\n\t\t\t\t\t2020;\n\t\t\t\t\t28:\n\t\t\t\t\t2252\u2013\n\t\t\t\t\t2270.","DOI":"10.1016\/j.ymthe.2020.06.025"},{"key":"2021080516155697600_i2590-017X-4-3-150-b12","doi-asserted-by":"crossref","unstructured":"Lee\n              DW,\n            \n            \n              Gardner\n              R,\n            \n            \n              Porter\n              DL,\n            \n            et al.\n          \n          Current concepts in the diagnosis and management of cytokine release syndrome.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2014;\n\t\t\t\t\t124:\n\t\t\t\t\t188\u2013\n\t\t\t\t\t195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2021080516155697600_i2590-017X-4-3-150-b13","doi-asserted-by":"crossref","unstructured":"Lee\n              DW,\n            \n            \n              Santomasso\n              BD,\n            \n            \n              Locke\n              FL,\n            \n            et al.\n          \n          ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector Cells.\n\t\t\t\t\tBiol Blood Marrow Transplant.\n\t\t\t\t\t2019;\n\t\t\t\t\t25:\n\t\t\t\t\t625\u2013\n\t\t\t\t\t638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2021080516155697600_i2590-017X-4-3-150-b14","doi-asserted-by":"crossref","unstructured":"Neelapu\n              SS,\n            \n            \n              Tummala\n              S,\n            \n            \n              Kebriaei\n              P,\n            \n            et al.\n          \n          Chimeric antigen receptor T-cell therapy: assessment and management of toxicities.\n\t\t\t\t\tNat Rev Clin Oncol.\n\t\t\t\t\t2018;\n\t\t\t\t\t15:\n\t\t\t\t\t47\u2013\n\t\t\t\t\t62.","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2021080516155697600_i2590-017X-4-3-150-b15","doi-asserted-by":"crossref","unstructured":"Park\n              JH,\n            \n            \n              Riviere\n              I,\n            \n            \n              Gonen\n              M,\n            \n            et al.\n          \n          Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2018;\n\t\t\t\t\t378:\n\t\t\t\t\t449\u2013\n\t\t\t\t\t459.","DOI":"10.1056\/NEJMoa1709919"},{"key":"2021080516155697600_i2590-017X-4-3-150-b16","doi-asserted-by":"crossref","unstructured":"Xhangolli\n              I,\n            \n            \n              Dura\n              B,\n            \n            \n              Lee\n              G,\n            \n            et al.\n          \n          Single-cell analysis of CAR-T cell activation reveals a mixed TH1\/TH2 response independent of differentiation.\n\t\t\t\t\tGenomics Proteomics Bioinformatics.\n\t\t\t\t\t2019;\n\t\t\t\t\t17:\n\t\t\t\t\t129\u2013\n\t\t\t\t\t139.","DOI":"10.1016\/j.gpb.2019.03.002"},{"key":"2021080516155697600_i2590-017X-4-3-150-b17","doi-asserted-by":"crossref","unstructured":"Chen\n              PH,\n            \n            \n              Lipschitz\n              M,\n            \n            \n              Weirather\n              JL,\n            \n            et al.\n          \n          Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.\n\t\t\t\t\tJCI Insight.\n\t\t\t\t\t2020;\n\t\t\t\t\t5:\n\t\t\t\t\te134612.","DOI":"10.1172\/jci.insight.134612"},{"key":"2021080516155697600_i2590-017X-4-3-150-b18","doi-asserted-by":"crossref","unstructured":"Suntharalingam\n              G,\n            \n            \n              Perry\n              MR,\n            \n            \n              Ward\n              S,\n            \n            et al.\n          \n          Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2006;\n\t\t\t\t\t355:\n\t\t\t\t\t1018\u2013\n\t\t\t\t\t1028.","DOI":"10.1056\/NEJMoa063842"},{"key":"2021080516155697600_i2590-017X-4-3-150-b19","doi-asserted-by":"crossref","unstructured":"van der Stegen\n              SJ,\n            \n            \n              Hamieh\n              M,\n            \n            \n              Sadelain\n              M.\n            \n          \n          The pharmacology of second-generation chimeric antigen receptors.\n\t\t\t\t\tNat Rev Drug Discov.\n\t\t\t\t\t2015;\n\t\t\t\t\t14:\n\t\t\t\t\t499\u2013\n\t\t\t\t\t509.","DOI":"10.1038\/nrd4597"},{"key":"2021080516155697600_i2590-017X-4-3-150-b20","doi-asserted-by":"crossref","unstructured":"Brudno\n              JN,\n            \n            \n              Kochenderfer\n              JN.\n            \n          \n          Toxicities of chimeric antigen receptor T cells: recognition and management.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2016;\n\t\t\t\t\t127:\n\t\t\t\t\t3321\u2013\n\t\t\t\t\t3330.","DOI":"10.1182\/blood-2016-04-703751"},{"key":"2021080516155697600_i2590-017X-4-3-150-b21","doi-asserted-by":"crossref","unstructured":"Le\n              RQ,\n            \n            \n              Li\n              L,\n            \n            \n              Yuan\n              W,\n            \n            et al.\n          \n          FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome.\n\t\t\t\t\tOncologist.\n\t\t\t\t\t2018;\n\t\t\t\t\t23:\n\t\t\t\t\t943\u2013\n\t\t\t\t\t947.","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"2021080516155697600_i2590-017X-4-3-150-b22","doi-asserted-by":"crossref","unstructured":"Nastoupil\n              LJ,\n            \n            \n              Jain\n              MD,\n            \n            \n              Feng\n              L,\n            \n            et al.\n          \n          Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2020;\n\t\t\t\t\t38:\n\t\t\t\t\t3119\u2013\n\t\t\t\t\t3128.","DOI":"10.1200\/JCO.19.02104"},{"key":"2021080516155697600_i2590-017X-4-3-150-b23","unstructured":"Oluwole\n              O,\n            \n            \n              Munoz\n              J,\n            \n            \n              Vose\n              JM,\n            \n            et al.\n          \n          Prophylactic steroid use with axicabtagene ciloleucel in patients with relapsed\/refractory large b-cell lymphoma. Abstract 70.\n\t\t\t\t\tPresented at: 2021 Transplantation and Cellular Therapy Meetings; Feb 8\u201312, 2021."},{"key":"2021080516155697600_i2590-017X-4-3-150-b24","doi-asserted-by":"crossref","unstructured":"Liu\n              S,\n            \n            \n              Deng\n              B,\n            \n            \n              Yin\n              Z,\n            \n            et al.\n          \n          Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia.\n\t\t\t\t\tBlood Cancer J.\n\t\t\t\t\t2020;\n\t\t\t\t\t10:\n\t\t\t\t\t15.","DOI":"10.1038\/s41408-020-0280-y"},{"key":"2021080516155697600_i2590-017X-4-3-150-b25","doi-asserted-by":"crossref","unstructured":"Strati\n              P,\n            \n            \n              Ahmed\n              S,\n            \n            \n              Furqan\n              F,\n            \n            et al.\n          \n          Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2019;\n\t\t\t\t\t133:\n\t\t\t\t\t2800\u2013\n\t\t\t\t\t2802.","DOI":"10.1182\/blood.2019000888"},{"key":"2021080516155697600_i2590-017X-4-3-150-b26","doi-asserted-by":"crossref","unstructured":"Taraseviciute\n              A,\n            \n            \n              Tkachev\n              V,\n            \n            \n              Ponce\n              R,\n            \n            et al.\n          \n          Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2018;\n\t\t\t\t\t8:\n\t\t\t\t\t750\u2013\n\t\t\t\t\t763.","DOI":"10.1158\/2159-8290.CD-17-1368"},{"key":"2021080516155697600_i2590-017X-4-3-150-b27","doi-asserted-by":"crossref","unstructured":"Taraseviciute\n              A,\n            \n            \n              Broglie\n              L,\n            \n            \n              Phelan\n              R,\n            \n            et al.\n          \n          What is the role of hematopoietic cell transplantation (HCT) for pediatric acute lymphoblastic leukemia (ALL) in the age of chimeric antigen receptor T-cell (CART) therapy?\n          \n            J Pediatr Hematol Oncol\n          .\n\t\t\t\t\t2019;\n\t\t\t\t\t41:\n\t\t\t\t\t337\u2013\n\t\t\t\t\t344.","DOI":"10.1097\/MPH.0000000000001479"},{"key":"2021080516155697600_i2590-017X-4-3-150-b28","doi-asserted-by":"crossref","unstructured":"Hu\n              Y,\n            \n            \n              Sun\n              J,\n            \n            \n              Wu\n              Z,\n            \n            et al.\n          \n          Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.\n\t\t\t\t\tJ Hematol Oncol.\n\t\t\t\t\t2016;\n\t\t\t\t\t9:\n\t\t\t\t\t70.","DOI":"10.1186\/s13045-016-0299-5"},{"key":"2021080516155697600_i2590-017X-4-3-150-b29","doi-asserted-by":"crossref","unstructured":"Gust\n              J,\n            \n            \n              Taraseviciute\n              A,\n            \n            \n              Turtle\n              CJ.\n            \n          \n          Neurotoxicity associated with CD19-targeted CAR-T cell therapies.\n\t\t\t\t\tCNS Drugs.\n\t\t\t\t\t2018;\n\t\t\t\t\t32:\n\t\t\t\t\t1091\u2013\n\t\t\t\t\t1101.","DOI":"10.1007\/s40263-018-0582-9"},{"key":"2021080516155697600_i2590-017X-4-3-150-b30","doi-asserted-by":"crossref","unstructured":"Santomasso\n              BD,\n            \n            \n              Park\n              JH,\n            \n            \n              Salloum\n              D,\n            \n            et al.\n          \n          Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2018;\n\t\t\t\t\t8:\n\t\t\t\t\t958\u2013\n\t\t\t\t\t971.","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2021080516155697600_i2590-017X-4-3-150-b31","doi-asserted-by":"crossref","unstructured":"Deng\n              Q,\n            \n            \n              Han\n              G,\n            \n            \n              Puebla-Osorio\n              N,\n            \n            et al.\n          \n          Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.\n\t\t\t\t\tNat Med.\n\t\t\t\t\t2020;\n\t\t\t\t\t26:\n\t\t\t\t\t1878\u2013\n\t\t\t\t\t1887.","DOI":"10.1038\/s41591-020-1061-7"},{"key":"2021080516155697600_i2590-017X-4-3-150-b32","doi-asserted-by":"crossref","unstructured":"Parker\n              KR,\n            \n            \n              Migliorini\n              D,\n            \n            \n              Perkey\n              E,\n            \n            et al.\n          \n          Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies.\n\t\t\t\t\tCell.\n\t\t\t\t\t2020;\n\t\t\t\t\t183:\n\t\t\t\t\t126\u2013\n\t\t\t\t\t142e17.","DOI":"10.1016\/j.cell.2020.08.022"},{"key":"2021080516155697600_i2590-017X-4-3-150-b33","doi-asserted-by":"crossref","unstructured":"Strati\n              P,\n            \n            \n              Nastoupil\n              LJ,\n            \n            \n              Westin\n              J,\n            \n            et al.\n          \n          Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.\n\t\t\t\t\tBlood Adv.\n\t\t\t\t\t2020;\n\t\t\t\t\t4:\n\t\t\t\t\t3943\u2013\n\t\t\t\t\t3951.","DOI":"10.1182\/bloodadvances.2020002228"},{"key":"2021080516155697600_i2590-017X-4-3-150-b34","doi-asserted-by":"crossref","unstructured":"Giavridis\n              T,\n            \n            \n              van der Stegen\n              SJC,\n            \n            \n              Eyquem\n              J,\n            \n            et al.\n          \n          CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.\n\t\t\t\t\tNat Med.\n\t\t\t\t\t2018;\n\t\t\t\t\t24:\n\t\t\t\t\t731\u2013\n\t\t\t\t\t738.","DOI":"10.1038\/s41591-018-0041-7"},{"key":"2021080516155697600_i2590-017X-4-3-150-b35","doi-asserted-by":"crossref","unstructured":"Sterner\n              RM,\n            \n            \n              Sakemura\n              R,\n            \n            \n              Cox\n              MJ,\n            \n            et al.\n          \n          GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2019;\n\t\t\t\t\t133:\n\t\t\t\t\t697\u2013\n\t\t\t\t\t709.","DOI":"10.1182\/blood-2018-10-881722"},{"key":"2021080516155697600_i2590-017X-4-3-150-b36","doi-asserted-by":"crossref","unstructured":"Locke\n              FL,\n            \n            \n              Ghobadi\n              A,\n            \n            \n              Jacobson\n              CA,\n            \n            et al.\n          \n          Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t20:\n\t\t\t\t\t31\u2013\n\t\t\t\t\t42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"2021080516155697600_i2590-017X-4-3-150-b37","doi-asserted-by":"crossref","unstructured":"Cordeiro\n              A,\n            \n            \n              Bezerra\n              ED,\n            \n            \n              Hirayama\n              AV,\n            \n            et al.\n          \n          Late events after treatment with CD19-targeted chimeric antigen receptor modified T ells.\n\t\t\t\t\tBiol Blood Marrow Transplant.\n\t\t\t\t\t2020;\n\t\t\t\t\t26:\n\t\t\t\t\t26\u2013\n\t\t\t\t\t33.","DOI":"10.1016\/j.bbmt.2019.08.003"},{"key":"2021080516155697600_i2590-017X-4-3-150-b38","doi-asserted-by":"crossref","unstructured":"Strati\n              P,\n            \n            \n              Varma\n              A,\n            \n            \n              Adkins\n              S,\n            \n            et al.\n          \n          Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.\n\t\t\t\t\tHaematologica.\n\t\t\t\t\tPublished online Jul 30,2020.\n\t\t\t\t\tDOI: 10.3324\/haematol.2020.254045.","DOI":"10.3324\/haematol.2020.254045"},{"key":"2021080516155697600_i2590-017X-4-3-150-b39","doi-asserted-by":"crossref","unstructured":"Galli\n              E,\n            \n            \n              Allain\n              V,\n            \n            \n              Di Blasi\n              R,\n            \n            et al.\n          \n          G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma.\n\t\t\t\t\tBone Marrow Transplant.\n\t\t\t\t\t2002;\n\t\t\t\t\t55:\n\t\t\t\t\t2347\u2013\n\t\t\t\t\t2349.","DOI":"10.1038\/s41409-020-01006-x"},{"key":"2021080516155697600_i2590-017X-4-3-150-b40","doi-asserted-by":"crossref","unstructured":"Hashmi\n              H,\n            \n            \n              Bachmeier\n              C,\n            \n            \n              Chavez\n              JC,\n            \n            et al.\n          \n          Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.\n\t\t\t\t\tBr J Haematol.\n\t\t\t\t\t2019;\n\t\t\t\t\t187:\n\t\t\t\t\te35\u2013\n\t\t\t\t\te38.","DOI":"10.1111\/bjh.16155"},{"key":"2021080516155697600_i2590-017X-4-3-150-b41","doi-asserted-by":"crossref","unstructured":"Jacobson\n              CA,\n            \n            \n              Hunter\n              BD,\n            \n            \n              Redd\n              R,\n            \n            et al.\n          \n          Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2020;\n\t\t\t\t\t38:\n\t\t\t\t\t3095\u2013\n\t\t\t\t\t3106.","DOI":"10.1200\/JCO.19.02103"},{"key":"2021080516155697600_i2590-017X-4-3-150-b42","doi-asserted-by":"crossref","unstructured":"Pasquini\n              MC LF,\n            \n            \n              Herrera\n              AF,\n            \n            et al.\n          \n          Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US).\n\t\t\t\t\tBlood.\n\t\t\t\t\t2019;\n\t\t\t\t\t134(suppl 1):\n\t\t\t\t\t764.","DOI":"10.1182\/blood-2019-124750"},{"key":"2021080516155697600_i2590-017X-4-3-150-b43","doi-asserted-by":"crossref","unstructured":"Pasquini\n              MC,\n            \n            \n              Hu\n              ZH,\n            \n            \n              Curran\n              K,\n            \n            et al.\n          \n          Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.\n\t\t\t\t\tBlood Adv.\n\t\t\t\t\t2020;\n\t\t\t\t\t4:\n\t\t\t\t\t5414\u2013\n\t\t\t\t\t5424.","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"2021080516155697600_i2590-017X-4-3-150-b44","doi-asserted-by":"crossref","unstructured":"Riedell\n              RA,\n            \n            \n              Walling\n              C,\n            \n            \n              Nastoupil\n              LJ,\n            \n            et al.\n          \n          A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas.\n\t\t\t\t\t2020;\n\t\t\t\t\t26:\n\t\t\t\t\tS41\u2013\n\t\t\t\t\tS42.","DOI":"10.1016\/j.bbmt.2019.12.108"},{"key":"2021080516155697600_i2590-017X-4-3-150-b45","doi-asserted-by":"crossref","unstructured":"Svoboda\n              J,\n            \n            \n              Hatcher\n              JB,\n            \n            \n              Chong\n              EA.\n            \n          \n          Use of bendamustine for lymphodepletion before tisagenlecleucel (anti-CD19 CAR T cells) for aggressive B-cell lymphomas.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2019;\n\t\t\t\t\t134(suppl 1):\n\t\t\t\t\t1606.","DOI":"10.1182\/blood-2019-131482"},{"key":"2021080516155697600_i2590-017X-4-3-150-b46","doi-asserted-by":"crossref","unstructured":"Ghafouri\n              S,\n            \n            \n              Timmerman\n              J,\n            \n            \n              Larson\n              S,\n            \n            et al.\n          \n          Axicabtagene ciloleucel CAR T-cell therapy for relapsed\/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?\n          \n            Bone Marrow Transplant\n          .\n\t\t\t\t\t2021;\n\t\t\t\t\t56:\n\t\t\t\t\t974\u2013\n\t\t\t\t\t977.","DOI":"10.1038\/s41409-020-01099-4"},{"key":"2021080516155697600_i2590-017X-4-3-150-b47","doi-asserted-by":"crossref","unstructured":"Bennani\n              NN,\n            \n            \n              Maurer\n              M,\n            \n            \n              Nastoupil\n              LJ,\n            \n            et al.\n          \n          Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary CNS involvement: results from the US Lymphoma CAR T Consortium.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2019;\n\t\t\t\t\t134:\n\t\t\t\t\t763.","DOI":"10.1182\/blood-2019-129097"},{"key":"2021080516155697600_i2590-017X-4-3-150-b48","doi-asserted-by":"crossref","unstructured":"Frigault\n              MJ,\n            \n            \n              Dietrich\n              J,\n            \n            \n              Martinez-Lage\n              M,\n            \n            et al.\n          \n          Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2019;\n\t\t\t\t\t134:\n\t\t\t\t\t860\u2013\n\t\t\t\t\t866.","DOI":"10.1182\/blood.2019001694"},{"key":"2021080516155697600_i2590-017X-4-3-150-b49","doi-asserted-by":"crossref","unstructured":"Strati\n              P,\n            \n            \n              Nastoupil\n              LJ,\n            \n            \n              Fayad\n              LE,\n            \n            et al.\n          \n          Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2019;\n\t\t\t\t\t133:\n\t\t\t\t\t2800\u2013\n\t\t\t\t\t2802.","DOI":"10.1182\/blood.2019000888"},{"key":"2021080516155697600_i2590-017X-4-3-150-b50","doi-asserted-by":"crossref","unstructured":"Gibson\n              TM,\n            \n            \n              Morton\n              LM,\n            \n            \n              Shiels\n              MS,\n            \n            et al.\n          \n          Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study.\n\t\t\t\t\tAIDS.\n\t\t\t\t\t2014;\n\t\t\t\t\t28:\n\t\t\t\t\t2313\u2013\n\t\t\t\t\t2318.","DOI":"10.1097\/QAD.0000000000000428"},{"key":"2021080516155697600_i2590-017X-4-3-150-b51","doi-asserted-by":"crossref","unstructured":"Abramson\n              JS,\n            \n            \n              Irwin\n              KE,\n            \n            \n              Frigault\n              MJ,\n            \n            et al.\n          \n          Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.\n\t\t\t\t\tCancer.\n\t\t\t\t\t2019;\n\t\t\t\t\t125:\n\t\t\t\t\t3692\u2013\n\t\t\t\t\t3698.","DOI":"10.1002\/cncr.32411"},{"key":"2021080516155697600_i2590-017X-4-3-150-b52","doi-asserted-by":"crossref","unstructured":"Dierickx\n              D,\n            \n            \n              Habermann\n              TM:\n            \n          \n          Post-transplantation lymphoproliferative disorders in adults.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2018;\n\t\t\t\t\t378:\n\t\t\t\t\t549\u2013\n\t\t\t\t\t562.","DOI":"10.1056\/NEJMra1702693"},{"key":"2021080516155697600_i2590-017X-4-3-150-b53","doi-asserted-by":"crossref","unstructured":"Mamlouk\n              O,\n            \n            \n              Nair\n              R,\n            \n            \n              Iyer\n              SP,\n            \n            et al.\n          \n          Safety and efficacy of CAR T-cell therapy in kidney transplant recipients.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2021;\n\t\t\t\t\t137:\n\t\t\t\t\t2558\u2013\n\t\t\t\t\t2562.","DOI":"10.1182\/blood.2020008759"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/4\/3\/150\/2880619\/i2590-017x-4-3-150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/4\/3\/150\/2880619\/i2590-017x-4-3-150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:30Z","timestamp":1765475310000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/4\/3\/article-p150.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,8,5]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-21-2","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}